TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06694480: Study of FID-022 in Participants With Advanced Solid Tumors

Sponsor: Fulgent Pharma LLC. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$691,152

Rescue Site Savings

+$471,240

Unlock Full NCT06694480 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06694480 Rescue Dossier →